Search Results - David Wesche

PBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profile by Karen Rowland Yeo, David Wesche

Connect to this object online.

Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders by Craig R. Rayner, Patrick F. Smith, Kevin Hershberger, David Wesche

Connect to this object online.

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial... by Kayla Ann Andrews, Joel S. Owen, James McCarthy, David Wesche, Nathalie Gobeau, Thaddeus H. Grasela, Jörg J. Möhrle

Connect to this object online.

The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation. by Nolan D Wood, Danelle Smith, Sally A Kinrade, Mark T Sullivan, Craig R Rayner, David Wesche, Kashyap Patel, Karen Rowland-Yeo

Connect to this object online.

Development and application of a PBPK modeling strategy to support antimalarial drug development by Nada Abla, Eleanor Howgate, Karen Rowland‐Yeo, Maurice Dickins, Mackenzie C. Bergagnini‐Kolev, Kuan‐Fu Chen, Savannah McFeely, Jennifer J. Bonner, Laura G. A. Santos, Nathalie Gobeau, Howard Burt, Zoe Barter, Hannah M. Jones, David Wesche, Susan A. Charman, Jörg J. Möhrle, Jeremy N. Burrows, Lisa M. Almond

Connect to this object online.